Earth Science Tech, Inc. (OTC: ETST) reported fiscal first-quarter 2027 results that underscore the company's robust financial health and strategic momentum. The company's net income surged 57% year-over-year to $715,697, driven by revenue of $9.0 million, a 3% increase from the prior-year period. Gross profit climbed to $6.3 million, while operating cash flow more than doubled to $707,131, reflecting improved operational efficiency. Total assets grew to $10.4 million, and diluted earnings per share improved to $0.003 from $0.001.
A notable highlight of the quarter was the company's capital management efforts: it repurchased and retired over 3.7 million common shares without incurring additional debt. This move signals confidence in the company's future prospects and a commitment to enhancing shareholder value. All key operating subsidiaries remained profitable, and the company continued to expand the licensing footprint of its compounding pharmacy operations across the United States. Management is also evaluating opportunities to broaden its telehealth and pharmacy fulfillment platforms, which could further solidify its integrated healthcare model.
The company's strategic initiatives are set to be discussed at its annual shareholder meeting scheduled for Aug. 31, 2026. Investors will vote on proposals including the cancellation of the company's Series B Preferred Stock and receive updates on a potential exchange uplisting. An uplisting could improve liquidity and market visibility, making the stock more accessible to a broader range of investors. This move is part of a broader effort to enhance the company's capital markets profile and attract institutional interest.
Earth Science Tech operates as a diversified holding company focused on the health and wellness sector. Its principal strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The company's healthcare operations are supported by investments in real estate and asset management activities, as well as a consumer products business. The core of its value proposition lies in the seamless integration of patient care, from consultation to fulfillment, achieved through the synergy of specialized subsidiaries.
These results come at a time when the healthcare sector is increasingly focused on integrated care models and telemedicine adoption. Earth Science Tech's ability to generate significant net income growth while expanding its operational footprint positions it well to capitalize on these trends. The company's focus on profitability and strategic expansion suggests a positive outlook for the remainder of the fiscal year. Investors and stakeholders will be watching closely to see how the company executes on its growth plans and whether the uplisting materializes, as these factors could significantly impact its market valuation and long-term success.
